CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8(+) T cells via lysosome-dependent degradation of TCF-1.
TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8(+) T cells via lysosome-dependent degradation of TCF-1.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CD8+ T细胞耗竭期间TCF-1减少会削弱抗肿瘤活性并降低对免疫检查点抑制剂的应答,但TCF-1如何下调尚不清楚。在此,我们发现,CD8+ T细胞耗竭过程中,转录因子TOX诱导的lnc-SUMF2-8可结合胞质中的TCF-1,并将其引导至溶酶体降解。TCF-1减少会促进前体耗竭T细胞(Tex prog)向中间/效应耗竭T细胞(Tex int/eff)分化,并进一步推动有功能的Tex细胞进入完全功能障碍的终末耗竭状态(Tex term)。
我们证明,T细胞耗竭期间TCF-1减少始于lnc-SUMF2-8依赖的TCF-1蛋白溶酶体降解,随后伴随TCF7 mRNA转录抑制。敲除lnc-SUMF2-8可阻止TCF-1溶酶体降解,在Tex细胞中维持TCF-1水平稳定,从而扩增可应答抗PD-1的Tex prog细胞,并增强功能性CD8+ T细胞持久性。
我们的研究提示,靶向lnc-SUMF2-8可增强抗肿瘤CD8+ T细胞功能,并协同提高抗PD-1治疗和CAR-T 细胞疗法的疗效。
The reduction of TCF-1 during CD8 + T cell exhaustion leads to attenuated antitumor activity and diminished responsiveness to immune checkpoint inhibitors.
However, how TCF-1 is downregulated remains unclear. Here, we showed that during CD8 + T cell exhaustion, lnc-SUMF2-8, induced by transcription factor TOX, can bind to cytosolic TCF-1 and direct it to the lysosome for degradation. The reduction of TCF-1 promotes Tex prog differentiation into Tex int/eff and further drives functional Tex cells into a fully dysfunctional Tex term state.
We demonstrated that TCF-1 reduction during T cell exhaustion is initiated by lnc-SUMF2-8-dependent lysosomal degradation of TCF-1 protein, followed by transcriptional suppression of TCF7 mRNA. Deletion of lnc-SUMF2-8 blocks lysosomal TCF-1 degradation, which maintains stable TCF-1 levels in Tex cells, thereby expanding the anti-PD-1-responsive Tex prog cells and enhances the persistence of functional CD8 + T cells.
Our findings suggest that targeting lnc-SUMF2-8 could enhance the function of the antitumor CD8 + T cells and synergistically improve the efficacy of anti-PD-1 treatment and CAR-T cell therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。